Company:  EPIZYME, INC.
Form Type:  4
Filing Date:  8/11/2022 
CIK:  0001571498 
Address:  400 TECHNOLOGY SQUARE
4TH FLOOR
 
City, State, Zip:  CAMBRIDGE, Massachusetts 02139 
Telephone:  617-229-5872 
Fiscal Year:  12/31 
Description of Business
The ongoing COVID-19 pandemic continues to have widespread, evolving, and unpredictable impacts on global economies, financial markets, business practices and societies. We are closely monitoring the impact of the COVID-19 pandemic and related developments on our business, operations and financial performance. Our focus remains on continuing to advance our efforts with respect to the commercialization of TAZVERIK® and to continue to advance the development of our pipeline, while making the health and safety of our employees and their families, healthcare providers, patients and communities a top priority. We believe that the COVID-19 pandemic has had an adverse impact on sales of TAZERIK and the initiation of clinical trials since the June 2020 FDA approval of TAZVERIK for follicular lymphoma, or FL.
Register and access this filing in:     
  FORM 4
    NAME AND TITLE
    NON DERIVATIVE SECURITIES
    DERIVATIVE SECURITIES
    EXPLANATIONS AND REMARKS
    REPORTING OWNERS
    SIGNATURES